Outcome of the Board Meeting held on Thursday, 13th November, 2025 and submission of Un-Audited Financial Results (Standalone) for the Second Quarter and Half year ended on 30th September, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gujarat Inject Kerala Ltd's Board approved un-audited standalone financial results for Q2 FY26 and half-year ended September 30, 2025. Revenue from operations for Q2 FY26 stood at ₹157.63 lakhs, a sharp decline of about 82% from ₹861.09 lakhs in Q2 FY25. For H1 FY26, revenue fell to ₹399.75 lakhs versus ₹1,165.63 lakhs in H1 FY25, a drop of roughly 66%. Profit after tax for H1 FY26 was ₹14.10 lakhs (down from ₹73.24 lakhs in H1 FY25), with Q2 PAT at ₹6.75 lakhs. EPS stood at ₹0.05 for the quarter and ₹0.10 for the half-year. The company's other equity remains negative at ₹(448.13) lakhs, indicating accumulated losses. Statutory auditors M/s. S. Mandawat & Co. issued a clean limited review report with no qualifications.
The sharp year-on-year decline in both revenue and profits signals significant business contraction, which is likely to be viewed negatively by shareholders. The negative other equity position raises concerns about long-term financial sustainability despite a positive quarterly profit.